579 related articles for article (PubMed ID: 23178916)
1. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
Paul C; van de Kerkhof P; Puig L; Unnebrink K; Goldblum O; Thaçi D
Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
Thaçi D; Unnebrink K; Sundaram M; Sood S; Yamaguchi Y
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):353-360. PubMed ID: 24846518
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.
Khobzey K; Liskova I; Szegedi A; Pavlovsky L; Lunder T; Kingo K; Miljković J; Péč J; Bohinc M; Hojnik M
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):11-14. PubMed ID: 28352929
[TBL] [Abstract][Full Text] [Related]
6. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
[TBL] [Abstract][Full Text] [Related]
7. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
Tillett W; Egeberg A; Sonkoly E; Gorecki P; Tjärnlund A; Buyze J; Wegner S; McGonagle D
Arthritis Res Ther; 2023 Sep; 25(1):169. PubMed ID: 37715294
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis.
Bongiorno MR; Pistone G; Doukaki S; Aricò M
Dermatol Ther; 2008 Oct; 21 Suppl 2():S15-20. PubMed ID: 18837728
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
Zangrilli A; Bavetta M; Scaramella M; Bianchi L
G Ital Dermatol Venereol; 2018 Apr; 153(2):146-154. PubMed ID: 29564871
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.
Van den Bosch F; Manger B; Goupille P; McHugh N; Rødevand E; Holck P; van Vollenhoven RF; Leirisalo-Repo M; Fitzgerald O; Kron M; Frank M; Kary S; Kupper H
Ann Rheum Dis; 2010 Feb; 69(2):394-9. PubMed ID: 19815494
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
12. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
Kokolakis G; Vadstrup K; Hansen JB; Carrascosa JM
Dermatology; 2022; 238(4):620-629. PubMed ID: 34823247
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.
Poulin Y; Crowley JJ; Langley RG; Unnebrink K; Goldblum OM; Valdecantos WC
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):882-90. PubMed ID: 23790018
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
Revicki DA; Menter A; Feldman S; Kimel M; Harnam N; Willian MK
Health Qual Life Outcomes; 2008 Oct; 6():75. PubMed ID: 18831744
[TBL] [Abstract][Full Text] [Related]
15. Treatment of psoriasis and psoriatic arthritis.
Papoutsaki M; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
[TBL] [Abstract][Full Text] [Related]
16. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M
Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
[TBL] [Abstract][Full Text] [Related]
18. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
Jemec GB; Ibler KS
J Drugs Dermatol; 2012 Aug; 11(8):939-42. PubMed ID: 22859238
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study.
Asahina A; Torii H; Ohtsuki M; Tokimoto T; Hase H; Tsuchiya T; Shinmura Y; Reyes Servin O; Nakagawa H
J Dermatol; 2016 Nov; 43(11):1257-1266. PubMed ID: 27129439
[TBL] [Abstract][Full Text] [Related]
20. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial.
Zhu B; Edson-Heredia E; Guo J; Maeda-Chubachi T; Shen W; Kimball AB
Br J Dermatol; 2014 Nov; 171(5):1215-9. PubMed ID: 24749812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]